Repros Therapeutics Inc. (RPRX) announced after the bell Wednesday that Androxal met both co-primary endpoints in its first pivotal study.
Repros Therapeutics gapped open dramatically higher Thursday, but traded in a range throughout the session. Shares finished with a gain of 6.97 at $16.10 on the highest volume of the year. The stock surged to a 2-month high and re-crossed both its 50 and 200-day moving averages.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.